As of 2025-02-13, the EV/EBITDA ratio of BioCryst Pharmaceuticals Inc (BCRX) is -66.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BCRX's latest enterprise value is 2,598.28 mil USD. BCRX's TTM EBITDA according to its financial statements is -39.34 mil USD. Dividing these 2 quantities gives us the above BCRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
Range | Selected | |
Trailing P/E multiples | 14.6x - 17.0x | 15.7x |
Forward P/E multiples | 17.9x - 24.6x | 22.8x |
Fair Price | (6.96) - (6.78) | (7.22) |
Upside | -177.4% - -175.4% | -180.3% |
Date | EV/EBITDA |
2025-02-07 | -64.62 |
2025-02-06 | -64.67 |
2025-02-05 | -64.04 |
2025-02-04 | -61.30 |
2025-02-03 | -58.83 |
2025-01-31 | -60.30 |
2025-01-30 | -60.15 |
2025-01-29 | -60.93 |
2025-01-28 | -60.46 |
2025-01-27 | -60.88 |
2025-01-24 | -58.93 |
2025-01-23 | -59.41 |
2025-01-22 | -58.83 |
2025-01-21 | -58.78 |
2025-01-17 | -57.93 |
2025-01-16 | -55.88 |
2025-01-15 | -56.78 |
2025-01-14 | -56.78 |
2025-01-13 | -60.46 |
2025-01-10 | -59.09 |
2025-01-08 | -61.09 |
2025-01-07 | -61.57 |
2025-01-06 | -59.93 |
2025-01-03 | -59.25 |
2025-01-02 | -59.93 |
2024-12-31 | -58.30 |
2024-12-30 | -58.36 |
2024-12-27 | -59.30 |
2024-12-26 | -59.36 |
2024-12-24 | -59.09 |
2024-12-23 | -59.67 |
2024-12-20 | -58.57 |
2024-12-19 | -57.62 |
2024-12-18 | -57.20 |
2024-12-17 | -58.14 |
2024-12-16 | -57.99 |
2024-12-13 | -58.36 |
2024-12-12 | -58.72 |
2024-12-11 | -60.09 |
2024-12-10 | -60.46 |
2024-12-09 | -59.41 |
2024-12-06 | -58.78 |
2024-12-05 | -59.99 |
2024-12-04 | -57.30 |
2024-12-03 | -56.57 |
2024-12-02 | -57.57 |
2024-11-29 | -58.20 |
2024-11-27 | -58.20 |
2024-11-26 | -58.14 |
2024-11-25 | -56.99 |